Multiple Myeloma

Multiple Myeloma

Comprehensive CRISPR-Cas9 Screens Identify Genetic Determinants of Drug Responsiveness in Multiple Myeloma

The introduction of new drugs in the past years has substantially improved outcome in multiple myeloma.

Blood Advances
Targeting Phosphoinositide 3-Kinases and Histone Deacetylases in Multiple Myeloma

Because the histone deacetylase and phosphoinositide 3-kinase pathway is a key signal in cancer cell biology, study investigators examine whether dual HDAC and PI3K inhibitors...

Experimental Hematology & Oncology
Immunological Prognostic Factors in Multiple Myeloma

The authors focus on characterizing the components of the immune system that are of prognostic value in MM patients, in order to facilitate the development of...

International Journal of Molecular Sciences

Preclinical Activity and Determinants of Response of the GPRC5DxCD3 Bispecific Antibody Talquetamab in Multiple Myeloma

Talquetamab, the new GPRC5DxCD3 bispecific antibody, actively kills GPRC5D+ MM cell lines and primary MM cells in vitro.

Blood Advances
Pathway-Directed Therapy in Multiple Myeloma

There are several pathways that can be targeted in myeloma, and, in combination with personalized medicine, some have shown promising results. 

Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma

The goal of this review is to summarize the understanding of the problem of resistance to these drugs, which is ultimately responsible for patient fatality.

Employment of Artificial Intelligence Based on Routine Laboratory Results for the Early Diagnosis of Multiple Myeloma

In order to enhance the detection rate of multiple myeloma and execute an early and more precise disease management, an artificial intelligence assistant diagnosis system is developed.

Frontiers in Oncology
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

The intent of this paper is to summarize the current major results of monoclonal antibody treatments in multiple myeloma.

The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and Challenges

Here, authors provide a critical review of the literature on the role of lipids and lipoproteins in MM pathophysiology.

Frontiers in Oncology
Melphalan Flufenamide Receives Accelerated Approval for Relapsed/Refractory Multiple Myeloma

Melphalan flufenamide, in combination with dexamethasone, has received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory MM who have received...

ASH Clinical News
Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

Study investigators examine the distribution of different subsets of monocytes in blood and bone marrow of newly-diagnosed untreated MGUS, smoldering and active MM, and its relationship with...

Circulating Plasma Cells as a Biomarker to Predict Newly Diagnosed Multiple Myeloma Prognosis: Developing Nomogram Prognostic Models

This study investigates the prognostic value of circulating plasma cells and establish novel nomograms to predict individual PFS as well as OS of patients with newly diagnosed multiple myeloma.

Frontiers in Oncology
Study Highlights Need to Protect Multiple Myeloma Patients From Infection

While there have been significant advancements in multiple myeloma treatment, infections—particularly bacterial and viral—remain major causes of morbidity and mortality among these patients...

Oncology Times - Latest Articles
Multiple Myeloma: MMRF CureCloud Study Updates

The registry is designed to be the most comprehensive database of clinical and genomic information from thousands of patients with MM in the first at-home genomic testing program.

Oncology Times - Latest Articles
Reovirus-Induced Cell-Mediated Immunity for the Treatment of Multiple Myeloma Within the Resistant Bone Marrow Niche

This study uses human peripheral blood mononuclear cells from healthy donors and in vitro co-culture of MM cells and BM stromal cells to recapitulate the resistant BM niche.

Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression

This review summarizes the main cellular and molecular alterations observed in MM patients’ immune system. 

Boosting Immunity Against Multiple Myeloma

This review focuses on current and future immunotherapies used in multiple myeloma with impact on bone marrow immune microenvironment cells, also known as the bone marrow immunome.

HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients

This study evaluates the impact of the HLC pair suppression on the rate of bloodstream infections and early death in 115 newly diagnosed MM patients.

Frontiers in Oncology
Older Patients With Multiple Myeloma May Be Able to Avoid Long-Term Steroid Use

A new study published by Larocca et al finds that switching select older patients to a lower dose of lenalidomide and discontinuing dexamethasone after 9 months was not only safe, but also yielded

The ASCO Post
Rheumatologic Diseases Impact the Risk of Progression of MGUS to Overt Multiple Myeloma

The risk of progression is doubled for MGUS patients with non-Ab–mediated RDs compared with those without concomitant RDs.

Blood Advances
BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma

Inhibitors of the BCL2 family represent an exciting new class of drugs with a novel mechanism of action that are likely to have activity as single agents and in combination with existing myeloma...

Suppression of Multiple Myeloma by Mitochondrial Targeting

Treatment of multiple myeloma aims at inducing cell apoptosis by surpassing the limited capacity of MM cells to cope with oxidative stress.

Scientific Reports
A Phase I Study of Anti‐BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Leukemia

This study is designed to assess the safety and preliminary efficacy of a novel anti‐B‐cell maturation antigen CAR T cell in R/R MM and PCL.

Clinical and Translational Medicine
Novel Experimental Drugs for Treatment of Multiple Myeloma

In this review, study investigators report the results of these new therapies and explored their potential applications.

Isatuximab as Monotherapy and Combined With Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

In myeloma patients with a median 4 prior therapy lines, adding dexamethasone to isatuximab increased response rates from 23.9% to 43.6%.

Triplet Combination Prolongs PFS in R/R Multiple Myeloma

A combination of daratumumab subcutaneous plus pomalidomide and dexamethasone is an effective and convenient treatment for patients with R/R MM who had received 1 or more lines...

Oncology Times - Latest Articles
Once-Weekly Selinexor Plus Bortezomib/Dexamethasone vs Twice-Weekly Bortezomib/Dexamethasone in Multiple Myeloma

The phase III BOSTON trial has shown significantly prolonged PFS with once-weekly selinexor plus bortezomib/dexamethasone vs twice-weekly bortezomib/dexamethasone in previously treated MM.

The ASCO Post
Spinal Cord Compression as a Consequence of Spinal Plasmacytoma in a Patient With Multiple Myeloma

This case report highlights a 46-year-old gentleman with MM that had resulted in neural compression in the lumbar and thoracic areas.

Clinics and Practice
Clinical Characteristics and Risk Factors for Pleural Effusion in Patients with Multiple Myeloma

The aim of this study is to investigate the characteristics and identify risk factors for occurrence of pleural effusion in multiple myeloma.

International Journal of General Medicine
FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma

The FDA just granted accelerated approval to Pepaxto in combination with dexamethasone for adult patients with R/R multiple myeloma who have received at least four prior lines of therapy...

The ASCO Post
Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: A Systematic Review and Meta-Analysis of 950 Patients

Despite multiple myeloma being largely incurable, use of CAR T therapy as a treatment for MM is a novel approach that is associated with impressive outcomes in heavily pretreated patients.

Blood Advances
Anti-BCMA CAR T Administration in a Relapsed and Refractory Multiple Myeloma Patient After COVID-19 Infection

This case reports details successful treatment of a R/R multiple myeloma patient treated with an anti-BCMA CAR T cell therapy immediately following clinical recovery from COVID-19.

Journal of Medical Case Reports
Daratumumab Plus RVd for Newly Diagnosed Multiple Myeloma: Final Analysis of the Safety Run-in Cohort of GRIFFIN

The phase 2 GRIFFIN study of daratumumab plus lenalidomide/bortezomib/dexamethasone for transplant-eligible, newly diagnosed MM includes a safety run-in phase followed by a randomized phase.

Blood Advances
Management of Patients With Multiple Myeloma Beyond the Clinical-Trial Setting: Understanding the Balance Between Efficacy, Safety and Tolerability, and Quality of Life

This review assesses the current instruments, methodologies, and recent initiatives for analyzing the MM patient experience.

Blood Cancer Journal
SARS-CoV-2 Vaccines in Patients With Multiple Myeloma

In both a pooled analysis of 23 studies with data from 412 patients with MM and a retrospective study including 650 patients with MM and COVID-19, the estimated risk of death due to COVID-19 was 33

Targeting NSD2-Mediated SRC-3 Liquid–Liquid Phase Separation Sensitizes Bortezomib Treatment in Multiple Myeloma

This study finds that high steroid receptor coactivator-3 expression is correlated with relapse/refractory and poor outcomes in MM patients treated with bortezomib-based regimens.

Nature Communications
Triplet Combo Regimen Yields Significant Clinical Benefit in Relapsed/Refractory MM

Real-world study findings presented at the virtual ESMO Congress show that therapy with ixazomib plus lenalidomide and dexamethasone yields significant clinical benefits...

Oncology Learning Network
Bortezomib-Based Triplet Therapy Shows No Benefit Over Doublet for MM With Acute Kidney Injury

Comparison of bortezomib-based triplet therapy regimen to a bortezomib doublet regimen shows no benefit in adding C-BD over BD for renal recovery in patients with MM and acute kidney injury.

Oncology Learning Network
Higher Rates of Sustained MRD Negativity Seen With Daratumumab-Containing Regimens Versus SOC in R/R Multiple Myeloma

Evaluation of MRD in the POLLUX and CASTOR trials shows that daratumumab-based regimens induce higher rates of sustained MRD negativity vs standard-of-care combination therapies.

Cancer Therapy Advisor

source list reference